Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease. - Wikidata - awgldk - TriplyDB

Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease.

Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease.

http://www.wikidata.org/entity/Q37582397

about

Vascular endothelial growth factor-B in physiology and disease Protection by Neuroglobin Expression in Brain Pathologies The role of astrocyte mitochondria in differential regional susceptibility to environmental neurotoxicants: tools for understanding neurodegeneration Meta-Analysis of Differential Connectivity in Gene Co-Expression Networks in Multiple Sclerosis.VEGF-B promotes recovery of corneal innervations and trophic functions in diabetic mice.Intranasal gene delivery for treating Parkinson's disease: overcoming the blood-brain barrier.Morphological Changes in a Severe Model of Parkinson's Disease and Its Suitability to Test the Therapeutic Effects of Microencapsulated Neurotrophic Factors.The glial cell-line derived neurotrophic factor: a novel regulator of intestinal barrier function in health and disease.Topographical Distribution of Morphological Changes in a Partial Model of Parkinson's Disease--Effects of Nanoencapsulated Neurotrophic Factors Administration.Gelatin-based hydrogel for vascular endothelial growth factor release in peripheral nerve tissue engineering.Insights into the Mechanisms Involved in Protective Effects of VEGF-B in Dopaminergic Neurons.Differential effects of the NMDA receptor antagonist MK-801 on dopamine receptor D1- and D2-induced abnormal involuntary movements in a preclinical model.Long-term effect of sub-anesthetic ketamine in reducing L-DOPA-induced dyskinesias in a preclinical model.Therapeutic effects of fucoidan in 6-hydroxydopamine-lesioned rat model of Parkinson's disease: Role of NADPH oxidase-1.Vascular endothelial growth factor-B: Impact on physiology and pathology.VEGF Signaling in Neurological Disorders.Deleterious Effects of VEGFR2 and RET Inhibition in a Preclinical Model of Parkinson's Disease.Loss of Pink1 modulates synaptic mitochondrial bioenergetics in the rat striatum prior to motor symptoms: concomitant complex I respiratory defects and increased complex II-mediated respiration.Long-Term Intravitreal Ranibizumab as a Potential Additional Risk Factor for Neurodegeneration in Parkinson's Disease: A Case Report.Outside in: Unraveling the Role of Neuroinflammation in the Progression of Parkinson's Disease

P2860

Q27003400-334E9139-3618-43EF-8060-D232A915CC17 Q28079997-4457BE4C-78B5-410E-91E7-0FE4931798C9 Q35145894-FB45954B-7412-4845-8284-031811315C65 Q37050779-7CFEB30A-ACAC-4628-8926-F9B861F379FC Q37587659-47252E96-850B-4286-9FD1-1F1CCD53F6BC Q38569775-0F554CB5-7C4B-4489-94C5-CA22D5AE3BAD Q38731068-264BB8B6-503E-463C-8834-88747FAF7D06 Q38772847-992BB1D6-5501-4963-BF1D-71CF5C25B96A Q38867773-BB7BB1F1-C8FE-43D2-A3FF-D5040FE4FE68 Q38982985-05ADF45C-5407-472C-954C-105D645EC922 Q39284965-776D23C9-17DE-4BB5-BA52-A30B235D7B5E Q39975159-12DA5D55-6529-4E79-9FA6-72971EC3F000 Q42106610-170C5A0E-5E89-47F0-B029-04721A484195 Q46814011-2986552D-A7DF-4D77-97CC-6D5A643C9CCB Q47450318-D683A42B-0EA0-46EE-8856-F86F1DEB3044 Q47860045-1FEEE0B3-ED5C-41D2-B889-D8E6AEEDD39B Q47907310-45CA0660-31EC-4277-B7A3-6E4F52AE66D6 Q48546626-DC294EB8-0AAE-4D4C-850D-F7BE9EFDCBE9 Q55317090-D0E9C1E4-48B3-42C2-8C9C-60843C1DCD18 Q59136331-CAD0F06B-D62F-4181-A1B5-C91ADC5D40D7

P2860

Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease.

http://www.wikidata.org/entity/Q37582397

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Comparative study of the neuro ...... models of Parkinson's disease.

@en

Comparative study of the neuro ...... models of Parkinson's disease.

@nl

type

label

Comparative study of the neuro ...... models of Parkinson's disease.

@en

Comparative study of the neuro ...... models of Parkinson's disease.

@nl

prefLabel

Comparative study of the neuro ...... models of Parkinson's disease.

@en

Comparative study of the neuro ...... models of Parkinson's disease.

@nl

P1433

Q37582397-8699C630-0219-454E-82FE-2D5225A5D883

P1476

Q37582397-76BEEAFD-F127-48ED-8318-6D905499FAC0

P2093

Q37582397-03878EBD-A342-402F-8599-DA7099073A4C

Q37582397-12780F64-F7BB-416E-A7CC-02371DF6D7A5

Q37582397-1F2E18FC-8C89-4A01-B851-4CCD4E8F16D1

Q37582397-46CB56FB-AA50-4E55-BB1B-098F36D09FBF

Q37582397-5024EA1F-6FC0-4F52-8546-0760CFD982B7

Q37582397-6453C2FB-ECED-4869-9DA6-185498FD2B65

Q37582397-7990A8C7-9EDD-4913-9144-46A42035E44E

Q37582397-B99E1D2A-8271-4AB6-9100-7E5E7DB392B0

Q37582397-E181A6C4-0FF5-4CD3-A362-EFAAA2E18054

Q37582397-F78CD8E9-E81B-4A30-80CD-12DDCEB41980

P2860

Q37582397-0758DDC1-233A-4855-B504-782917E0005F

Q37582397-090D1751-3DDB-4846-B37A-E30040860AEE

Q37582397-0D97149C-1BED-4CA3-A948-4F3A3F33AB3C

Q37582397-16F2BE12-23AC-4F6E-AE95-64E42D20C09D

Q37582397-19DF13B6-C75B-47B0-B5B4-989CC7568130

Q37582397-1A1DE7D1-FF9C-4953-83C9-F174DF71B36D

Q37582397-1E437453-1666-4AC9-8B92-F8E0E259EE1F

Q37582397-1E5C6321-1410-4A3A-B9E6-0879478B94DF

Q37582397-20F844E9-3093-4045-8A56-572E30FB89CD

Q37582397-26E67C8F-9E0F-473D-80F6-950863EA8A8A

P304

Q37582397-392F1001-9FDF-4222-82C6-5B47CB7556E3

P31

Q37582397-0F9542AC-7CBD-4130-915A-CE013F341730

P356

Q37582397-10DB00D0-1096-4726-9D70-14F2DEFD5E24

P407

Q37582397-C838D663-837C-4DE1-B3DD-D13E7AA8B182

P478

Q37582397-67CAE388-DB56-464B-90B9-9CCDCA0818A5

P577

Q37582397-361E4283-3711-40E7-B9D2-2A73607A4D82

P5875

Q37582397-4949F2EA-6566-441C-8C8A-66794BCE4298

P698

Q37582397-F1DE3D94-5E74-464C-95A6-6D7D44E42729

P932

Q37582397-8AEA3591-AE94-48EF-9B80-C703568CDD55

P356

J.NEUROSCIENCE.2013.11.038

P1433

P1476

Comparative study of the neuro ...... models of Parkinson's disease.

@en

P2093

B Caballero

http://www.w3.org/2001/XMLSchema#string

D J Hariri

http://www.w3.org/2001/XMLSchema#string

D W Mount

http://www.w3.org/2001/XMLSchema#string

M J Bartlett

http://www.w3.org/2001/XMLSchema#string

O Kaut

http://www.w3.org/2001/XMLSchema#string

S J Sherman

http://www.w3.org/2001/XMLSchema#string

S Zhang

http://www.w3.org/2001/XMLSchema#string

T Falk

http://www.w3.org/2001/XMLSchema#string

U Wüllner

http://www.w3.org/2001/XMLSchema#string

X Yue

http://www.w3.org/2001/XMLSchema#string

P2860

Rotenone, paraquat, and Parkinson's disease

Functional annotation of heart enriched mitochondrial genes GBAS and CHCHD10 through guilt by association

In search for function of two human orphan SDR enzymes: hydroxysteroid dehydrogenase like 2 (HSDL2) and short-chain dehydrogenase/reductase-orphan (SDR-O)

Genomic organization of the mouse and human genes for vascular endothelial growth factor B (VEGF-B) and characterization of a second splice isoform

VEGF-B inhibits apoptosis via VEGFR-1-mediated suppression of the expression of BH3-only protein genes in mice and rats

Functional recovery in parkinsonian monkeys treated with GDNF

How mitochondria produce reactive oxygen species

A nonsense mutation in COQ9 causes autosomal-recessive neonatal-onset primary coenzyme Q10 deficiency: a potentially treatable form of mitochondrial disease

A family of fatty acid transporters conserved from mycobacterium to man

The GDNF family: signalling, biological functions and therapeutic value

P304

385-400

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.NEUROSCIENCE.2013.11.038

http://www.w3.org/2001/XMLSchema#string

P407

P478

258

http://www.w3.org/2001/XMLSchema#string

P577

2013-11-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259109515

http://www.w3.org/2001/XMLSchema#string

P698

24291725

http://www.w3.org/2001/XMLSchema#string

P932

3923582

http://www.w3.org/2001/XMLSchema#string